Fernö M
Jubileum Institute, Department of Oncology, University Hospital, Lund, Sweden.
Anticancer Res. 1998 May-Jun;18(3C):2167-71.
Prognostic factors, e.g. metastatic disease, lymph node status, tumour size, histologic grade, estrogen and progesterone receptors, and markers of proliferation are used to predict the clinical course of breast cancer at the time of primary treatment. Patients with a poor prognosis are offered adjuvant therapy. For the choice of adjuvant therapy (endocrine or cytotoxic) treatment predictive factors, e.g. estrogen and progesterone receptor; are useful. Putative new prognostic factors (e.g. oncogenes, tumour suppressor genes, and invasive factors) should be evaluated together with the clinical established factors in multivariate analyses.
预后因素,如转移性疾病、淋巴结状态、肿瘤大小、组织学分级、雌激素和孕激素受体以及增殖标志物,用于预测初次治疗时乳腺癌的临床病程。预后较差的患者会接受辅助治疗。对于辅助治疗(内分泌或细胞毒性)的选择,治疗预测因素,如雌激素和孕激素受体,是有用的。在多变量分析中,应将假定的新预后因素(如癌基因、肿瘤抑制基因和侵袭因素)与临床已确定的因素一起进行评估。